This article was originally published in The Gray Sheet
Executive SummaryPlans to close its Argyle, New York tracheal tube manufacturing plant and transfer its operations to facilities in Athlone, Ireland; Irving, California; and Juarez, Mexico. The Argyle plant has about 450 employees, 30 of which are eligible for relocation, the company says. Mallinckrodt will hire additional staff at the new tracheal tube manufacturing sites but is not likely to fill all of the current positions due to overlap with existing positions at the locations. The high cost of labor at the Argyle plant as well as the increased efficiency of newer plants were cited by Mallinckrodt as reasons for the transfer of operations. The move is the largest part of a restructuring program, announced in June ("The Gray Sheet" June 20, p. 34), that is designed to create about $40 mil. per year in savings for Mallinckrodt by 1996. The firm recently restructured its sales force ("The Gray Sheet" June 20, p. 34) and plans to streamline its administrative staff for additional savings
You may also be interested in...
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.